ClinicalTrials.Veeva

Menu
H

Hacettepe University Hospital | Hematology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

JNJ-73763989
Guselkumab
JNJ-56136379
Interferon
JNJ-81201887
FP-045

Parent organization

This site is a part of Hacettepe University Hospital

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 18 total trials

A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia

This is a multi-center, Phase 1/2 study to determine the Optimal Biologic Dose (OBD) and to evaluate the safety, tolerability, PK, and preliminary ac...

Enrolling
Fanconi Anemia
Drug: FP-045

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Active, not recruiting
Crohn Disease
Drug: Guselkumab Dose 3
Drug: Placebo

The purpose of the study is to evaluate on-treatment efficacy against hepatitis D virus (HDV) of JNJ-73763989 + nucleos(t)ide analog (NA) regimen com...

Active, not recruiting
Hepatitis D, Chronic
Drug: Placebo
Drug: JNJ-73763989

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Enrolling
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

Trial sponsors

H
Janssen (J&J Innovative Medicine) logo
BioNTech logo
E
F
Janssen (J&J Innovative Medicine) logo
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems